Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Outstanding (Weighted Average) (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $63355.0 as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 2.21% to $63355.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63355.0 through Dec 2025, up 2.21% year-over-year, with the annual reading at $63355.0 for FY2025, 2.21% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $63355.0 at Fulcrum Therapeutics, down from $62.5 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $62.5 million in Q2 2025, with the low at $32636.0 in Q2 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $26.5 million, with a median of $62669.5 recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) tumbled 99.87% in 2022, then skyrocketed 151022.52% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $35361.0 in 2021, then increased by 27.23% to $44991.0 in 2022, then skyrocketed by 36.27% to $61310.0 in 2023, then grew by 1.1% to $61984.0 in 2024, then rose by 2.21% to $63355.0 in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $63355.0, $62.5 million, and $62.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.